Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study (CIK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01498055
Recruitment Status : Unknown
Verified December 2011 by Gong Liang, Third Military Medical University.
Recruitment status was:  Recruiting
First Posted : December 23, 2011
Last Update Posted : March 22, 2012
Information provided by (Responsible Party):
Gong Liang, Third Military Medical University

Brief Summary:
To study the efficacy and safety of autologous CIK cells infusion for the treatment of lung cancer.

Condition or disease
Lung Cancer

Detailed Description:
A randomized controlled trail on the efficacy and safety of autologous cytokine-induced killer (CIK) cells infusion treatment in advanced primary lung cancer

Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Randomized Controlled Trail on the Efficacy and Safety of Autologous Cytokine-induced Killer (CIK) Cells Infusion Treatment in Advanced Primary Lung Cancer
Study Start Date : December 2011
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

CIK therapy group
control group

Primary Outcome Measures :
  1. Disease Control Rates (DCR) [ Time Frame: From 12-2011 to 12-2013 ]
    Lung lesions of disease control rates DCR (CR + PR + SD), according to solid tumor response evaluation standard (response evaluation criteria in solid tumors, RECIST) standard

Secondary Outcome Measures :
  1. Overall Survival(OS) [ Time Frame: 2 years ]
    Disease progression-free surial (Progression-Free Srvival, PFS) with observations

Biospecimen Retention:   Samples With DNA
The one-time folic acid sodium anticoagulation vacuum picks bag, through the venous blood sampling 60 ml. When blood alcohol on parts of the need blood disinfects processing. After the department shows will seal in a sterile bag, 16-21 degrees Celsius save, and transported to a cell biological treatment as soon as possible a follow-up operation center GMP laboratory.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary lung cancer diagnosis (including small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma and large cell carcinoma) patients

Inclusion Criteria:

  • 18~70 year old, KPS score >50 points, estimate survival > 3 months;
  • Primary lung cancer patients after chemotherapy or radiation therapy;
  • Primary lung cancer patients after targeted therapy;
  • Primary lung cancer patients with lung function can not accept operation or unwilling to operation;
  • Primary lung cancer recurrence or surgery can't complete resection;
  • Primary lung cancer patients after intervention therapy(I125 implanted, freezing, rf, etc.);
  • No serious mental illness and no serious heart, liver, kidney diseases, unincorporated other potentially lethal diseases;
  • Patients Voluntary attempt, and informed consent.

Exclusion Criteria:

  • History of cardiovascular disease: congestive heart failure > New York heart association (NYHA) level II, unstable angina patients (resting when the angina symptoms) or new happen angina pectoris (recent 3 months) or recent 6 months of myocardial infarction;
  • Cachexia; or other deadly diseases;
  • Liver function laboratory ALT, AST more than normal limits on 2.0 times ; Or kidney TBIL, BUN more than normal limits on 1.0 times , or Cr more than normal upper limit;
  • Active infection;
  • Pregnant or lactating women
  • At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents);
  • Now or recently will join another experimental clinical study ;
  • Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, HIV infections, etc.), or influence on the results of clinical trials for analysis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01498055

China, Chong Qing
Liang Gong Recruiting
Chong Qing, Chong Qing, China, 400038
Contact: Liang Gong    13983965893   
Sub-Investigator: Liang Gong         
Sponsors and Collaborators
Third Military Medical University
Study Chair: Xiangdong Zhou Southwest Hospital Third Military University

Responsible Party: Gong Liang, MD, Third Military Medical University Identifier: NCT01498055     History of Changes
Other Study ID Numbers: GLiang
First Posted: December 23, 2011    Key Record Dates
Last Update Posted: March 22, 2012
Last Verified: December 2011

Keywords provided by Gong Liang, Third Military Medical University:
lung cancer
CIK cells

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases